Skip to main
HCAT
HCAT logo

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 20%
Hold 70%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc has demonstrated increasing earnings power over the past seven years, characterized by rising EBITDA, a growing client base, and a decline in headcount, indicating efficient operations. Executive insights from hospitals suggest that volume trends are exceeding budgetary expectations, which bodes well for further revenue generation and expansion of HCAT module sales. Additionally, potential upside risk is driven by the prospect of renewed revenue growth, enhanced volumes and insurance coverage, alongside improving margins.

Bears say

Health Catalyst Inc. is experiencing a slowdown in total revenue growth, raising concerns about future revenue and EBITDA growth, particularly due to the highly penetrated total addressable market (TAM) within the healthcare sector. Despite approximately 90% of its revenue being recurring, the company has seen a decline in net dollar-based retention levels, which could threaten its long-term financial stability. Additionally, the potential failure to deliver meaningful return on investment (ROI) could lead to a significant decrease in the company's relevancy in a competitive market.

HCAT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 20% recommend Buy, 70% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 10 analysts, HCAT has a Hold consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.